10-Q quarterly report · filed Nov 9, 2026

Foghorn Therapeutics Inc. (FHTX) Q3 2026 10-Q Quarterly Report

Short answer

Foghorn Therapeutics Inc. (FHTX) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $84M (up 924.7% year over year) with net income of $58M.

Q3 2026 key financials · XBRL

Revenue
$84M
+924.7% YoY · +419.8% QoQ
Net income
$58M
+466.9% YoY · +908.6% QoQ
Operating margin
67.8%
EPS (diluted)
$0.82
+415.4% YoY · +920.0% QoQ

Source: XBRL data from the Foghorn Therapeutics Inc. (FHTX) Q3 2026 10-Q on SEC EDGAR. USD.

Foghorn Therapeutics Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Collaboration revenue $83.5M, up $75.4M YoY from $8.2M, including $74.1M cumulative catch-up adjustment
  • Operating margin 67.8% vs negative 226.9% YoY, with operating income $56.6M vs loss of $18.5M
  • Lilly partnered programs, largest R&D line, $4.6M, down $2.2M YoY; early development costs increased $1.7M
  • Cash, equivalents and marketable securities $156.2M; nine-month operating cash outflow $61.4M
  • Near-term cost reductions expected from pipeline reprioritization and 40% workforce reduction; cash runway expected at least twelve months

Risk Factors

  • New clinical-development risk: FHD-909 and SMARCA2 degrader halted after Phase 1 data review
  • New workforce-reduction risk: strategic reprioritization cut approximately an undisclosed percentage of employees
  • Regulatory risk: IRS audit opened for tax year 2023, with potential outcomes under evaluation
  • Financial risk: accumulated deficit $601.4 million despite $31.1 million nine-month net income
  • Collaboration concentration risk: $74.1 million revenue recognized from Lilly program reprioritization નિર્ણ

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Foghorn Therapeutics Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.